Prognia
Drug Database
🇪🇺EU · EMAWithdrawnATC: B01AC30

Clopidogrel/Acetylsalicylic acid Teva(clopidogrel;acetylsalicylic acid)

Acute Coronary Syndrome;Myocardial Infarction

Marketing Authorisation Holder: Teva Pharma B.V.

EMA Authorisation: 01/09/2014

INN: clopidogrel;acetylsalicylic acid

Indication

Clopidogrel/Acetylsalicylic acid Teva is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). Clopidogrel/Acetylsalicylic acid Teva is a fixed?dose combination medicinal product for continuation of therapy in: Non?ST segment elevation acute coronary syndrome (unstable angina or non?Q?wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention ST segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Clopidogrel/Acetylsalicylic acid Teva — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.